Total number of resected lymph nodes predicts survival in esophageal cancer

Annals of Surgery

Volumn 248, Issue 2, 2008, Pages 221-226

  Altorki, Nasser K ^a,b   Zhou, Xi Kathy ^a   Stiles, Brendon ^a   Port, Jeffrey L ^a   Paul, Subroto ^a   Lee, Paul C ^a   Mazumdar, Madhu ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DATA BASE; DISEASE SEVERITY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; HAZARD RATIO; HUMAN; LYMPH NODE; LYMPH NODE DISSECTION; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ADENOCARCINOMA; AGE; CANCER INVASION; CANCER STAGING; DISEASE FREE SURVIVAL; ESOPHAGUS TUMOR; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; METASTASIS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK ASSESSMENT; SEX DIFFERENCE; SQUAMOUS CELL CARCINOMA; STATISTICS; SURVIVAL;

ADENOCARCINOMA; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEX FACTORS; SURVIVAL ANALYSIS;

EID: 49849089502     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31817bbe59     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142-146.
3. Blot WJ, DeVesa SS, Kneller RW, et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991;13:265:1287-1289.
4. Botterweck AA, Schouten LJ, Volovics A, et al. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int JEpdemiol. 2000;29:645-654.
5. Junginger T, Gockel I, Heckhoff S. A comparison of transhiatal and transthoracic resections on the prognosis in patients with squamous cell carcinoma of the esophagus. Eur J Surg Oncol. 2006;32:749-755.
6. Law S, Wong J. Lymph node dissection in surgical treatment of esophageal neoplasms. Surg Oncol Clin N Am. 2007;16:115-131.
7. Orringer MB, Marshall B, Chang AC, et al. Two thousand transhiatal esophagectomies: changing trends, lessons learned. Ann Surg. 2007;246: 363-372.
8. Hagen JA, DeMeester SR, Peters JH, et al. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg. 2001;234:520-530.
9. Altorki N, Kent M, Ferrara C, et al. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg. 2002;236:177-183.
10. Lerut T, Nafteux P, Moons J, et al. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg. 2004;240:962-972; discussion 972-974.
11. Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarci- noma of the esophagus. N Engl J Med. 2002;347:1662-1669.
12. Hulscher JBF, Van Sandick JW, Offerhaus GJ, et al. Prospective analysis of the diagnostic yield of extended en bloc resection for adenocarcinoma of the esophagus or gastric cardia. Br JSurg. 2001;88:715-719.
13. Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. J Clin Oncol. 2005;23:7114-7124.
14. Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. Ann Surg Oncol. 2007;14: 317-328.
15. Schwarz RE, Smith DD. Lymph node dissection impact on staging and survival of extrahepatic cholangiocarcinomas, based on U.S. population data. J Gastrointest Surg. 2007;11:158 -165.
16. Schwarz RE, Smith DD. Extent of lymph node retrieval and pancreatic cancer survival: Information from a large US population database. Ann Surg Oncol. 2006;13:1189-1200.
17. Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable esophageal cancer. J Gastrointest Surg. 2007;11:1384-1393.
18. Birkmeyer JD, Stukel TA, Siewers AE, et al. Surgeon volume and operative mortality in the United States. N Engl J Med. 2003;349:2117-2127.
19. Birkmeyer JD, Sun Y, Wong SL, et al. Hospital volume and late survival after cancer surgery. Ann Surg. 2007;245:777-783.
20. Altorki N, Skinner D. Should en bloc esophagectomy be the standard of care for esophageal carcinoma? Ann Surg. 2001;234:581-587.
21. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515-526.
22. Royston P, Altman DG. Regression using fractional polynomials of continuous covariates-parsimonious parametric modeling. R Stat Soc Ser C Appl Stat. 1994;43:429-467.
23. Havenga K, Enker WE, Norstein J, et al. Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1411 patients. Eur JSurg Oncol. 1999;25:368 -374.
24. Martling A, Holm T, Johansson H, et al. The Stockholm II trial on preoperative radiotherapy in rectal carcinoma: long-term follow-up of a population-based study. Cancer. 2001;15:92:896 -902.
25. Martling A, Holm T, Rutqvist LE, et al. Impact of a surgical training programme on rectal cancer outcomes in Stockholm. Br JSurg. 2005; 92:225-229.
26. Tsai HL, Lu CY, Hsieh JS, et al. The prognostic significance of total lymph node harvest in patients with T2-4N0M0 colorectal cancer. JGastrointest Surg. 2007;11:660 -665.
27. Sarli L, Bader G, Iusco D, et al. Number of lymph nodes examined and prognosis of TNM stage II colorectal cancer. Eur J Cancer. 2005;41: 272-279.
28. George S, Primrose J, Talbot R, et al. Will Rogers revisited: prospective observational study of survival of 3592 patients with colorectal cancer according to number of nodes examined by pathologists. Br J Cancer. 2006;95:841-847.
29. Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol. 2003;21:2912- 2919.
30. Sasaki M, Watanabe H, Jass JR, et al. Occult lymph node metastases detected by cytokeratin immunohistochemistry predict recurrence in "node negative" colorectal cancer. J Gastroenterol. 1997;32:758-764.
31. Bilchik AJ, Hoon DS, Saha S, et al. Prognostic impact of micrometas- tases in colon cancer: interim results of a prospective multicenter trial. Ann Surg. 2007;246:568 -575.
32. Rosenberg R, Hoos A, Mueller J, et al. Prognostic significance of cytokeratin-20 reverse transcriptase polymerase chain reaction in lymph nodes of node-negative colorectal cancer patients. J Clin Oncol. 2002; 5:20:1049-155.
33. Gu CD, Osaki T, Oyama T, et al. Detection of micrometastatic tumor cells in pN0 lymph nodes of patients with completely resected non-small cell lung cancer: impact on recurrence and Survival. Ann Surg. 2002; 235:133-139.
34. Izbicki JR, Hosch SB, Pichlmeier U, et al. Prognostic value of immu- nohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med. 1997;23: 337:1188-1194.